Samuel Hyde lecture. Polypharmacy in rheumatoid arthritis--help or hindrance?
The use of multiple drugs in treating rheumatoid arthritis is based on the assumption that their effects are additive. Sometimes the results are unexpected or the added drug may confer no additional benefit to the patient whilst leaving him more liable to undesirable side-effects. Some form of polypharmacy may be necessitated by the different pharmacological properties of our drugs. Certain drugs have been judged on their steroid-sparing effects allowing lower doses to be used and thereby reducing the toxicity of corticosteroids. It is likely that some potential areas of danger from interacting drugs have been over-emphasized, being based on speculative rather than real data or purely on animal experiments using non-clinical doses. The patient with active RA with a low serum albumin would be unusually susceptible to changes induced by combinations of strongly bound anti-inflammatory drugs. He would also be highly susceptible to side-effects, as has been shown with prednisone. Side-effects here are doubled when the patients serum albumin is below 2.5g/100ml(lewis et al.1971). I believe we should continue to ask ourselves whether by subtracting one or more drugs from the patients cocktail we may not produce a most welcome benefit for both patient and doctor and, I suppose we could even add, the hard-pressed tax payer.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D001241:Aspirin / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use / Q000652:urine; D008297:Male; D011485:Protein Binding; D012709:Serum Albumin
D000305:Adrenal Cortex Hormones; D012709:Serum Albumin; D001241:Aspirin; D007213:Indomethacin